Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Metformin for Abdominal Aortic Aneurysm Growth Inhibition

A multi-centre population-based open-label randomized controlled trial with allocation concealment and blinded outcome assessment will examine if up to 2g metformin daily slows AAA growth in patients with small AAAs who do not have diabetes.

aortic aneurysm
abdominal aortic aneurysm
metformin
aaas
aneurysm
  • 0 views
  • 16 Feb, 2024
  • 1 location
Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.

Metformin is a widely used anti-diabetic drug. Several studies have pointed out a potentially beneficial effect of metformin therapy in diabetic cancer patients.

cancer
metastasis
metformin
carcinoma
preoperative chemotherapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin

The aim of the study is to evaluate the effect of nilotinib on the pharmacokinetics and pharmacodynamics of metformin in healthy male adults

metformin
body mass index
  • 0 views
  • 05 Aug, 2020
Effect of Cassia Cinnamon on Arterial Stiffness Parameters in Patients With Type 2 Diabetes Mellitus

Type 2 diabetes mellitus is considered a serious public health problem that has been raising worldwide. In Mexico, it is an important cause of morbi - mortality and its characterized by hyperglycemia that promotes an increase of cardiovascular risk through the impairment of arterial stiffness and endothelial function, which, in …

  • 0 views
  • 16 Feb, 2024
  • 1 location
PCOS Treatment Using DLBS3233 and Metformin.

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 23 Sep, 2022
  • 3 locations
PCOS Treatment Using DLBS3233, Metformin, and Combination of Both (POSITIF)  

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 26 Oct, 2022
  • 4 locations
Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer

Glucose starvation and metformin have synergistic antitumor effects that are mediated through the concomitant inhibition of glycolysis and mitochondrial oxidative phosphorylation.

fmd regimen
potassium
HER2
serum fsh level
hysterectomy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Does Insulin Sensitivity Impact the Potential of Metformin to Slow Aging

The same subjects will provide a skeletal muscle biopsy pre-- and post-intervention to assess the change in mitochondrial function and mitochondrial remodeling with and without metformin treatment. By completion of this project, the investigators expect to provide evidence that helps further delineate who may benefit from metformin treatment to slow …

chronic disease
muscle biopsy
insulin resistance
a 12
metformin
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Altered Tumor Oxygenation by Metformin a Potential Step in Overcoming Radiotherapy Resistance in LACC

Hypoxia-modifying measures implemented in the clinic are lacking. Metformin is a well-known, well-tolerated and low-cost drug used for decades in the treatment of type 2- diabetes. Recent studies suggest an improved tumor oxygenation by metformin potentially improving radiotherapy response and patient outcome.

hypoxia
renal function test
carcinoma
hydronephrosis
serum pregnancy test
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study to Evaluate Safety Tolerability Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM) who are receiving metformin monotherapy

fasting
metformin
body mass index
plasma glucose
  • 0 views
  • 05 Aug, 2020